Pfizer’s Rapamune Receives FDA Approval for Treatment of Rare Lung Disease
Today, Pfizer Inc. announced that US health regulators approved the first drug to treat a rare, progressive lung disease.
The company said that the US Food and Drug Administration (FDA) approved its Rapamune (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system.
